Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Safety"

1765 News Found

Trial milestone sparks hope for first long-term gastroparesis treatment
Clinical Trials | March 19, 2026

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis


Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
News | March 17, 2026

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect


Cupid unveils “Made in India, Japanese Quality” branding to boost global presence
News | March 17, 2026

Cupid unveils “Made in India, Japanese Quality” branding to boost global presence

The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer


L&T Tech unveils AI-powered lung digital twin platform
Digitisation | March 17, 2026

L&T Tech unveils AI-powered lung digital twin platform

LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs


Johnson & Johnson reports promising early results for targeted bladder cancer therapy
Clinical Trials | March 17, 2026

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


First patient dosed in trial of novel drug targeting limb-threatening artery disease
News | March 16, 2026

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts


Finerenone hits major goal in Phase III FIND-CKD trial
Clinical Trials | March 16, 2026

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk